Applied Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Applied Therapeutics reports significant Q3 2025 net loss and ongoing liquidity concerns, alongside legal settlements and regulatory challenges for its lead drug candidates.
Applied Therapeutics reports significant losses and a going concern warning following FDA rejection of its lead drug for Classic Galactosemia and ongoing litigation.
Applied Therapeutics faces ongoing regulatory hurdles and leadership transitions while reporting a net loss of $21.8 million for Q1 2025.
Applied Therapeutics reports a net loss of $68.6 million for Q3 2024, while highlighting progress in its clinical programs and regulatory submissions.
Applied Therapeutics reports a net income of $2.9 million for the second quarter of 2024, a significant turnaround from a net loss of $29.6 million in the same period last year, driven by changes in warrant liabilities.
Applied Therapeutics reports a net loss of $83.9 million for Q1 2024, but secures $113.8 million in net proceeds through financing activities.